DOCSLIB.ORG

Archive Project and History Fund

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Archive Project and History Fund NEWSLINE HISTORY CORNER Archive Project and History Fund Frederic Fahey, DSc, Boston Children’s Hospital, Boston, MA s SNMMI historian, I would like to share some of the of Excellence, the SNMMI imple- ongoing projects as well as thoughts on ways in which mented the Saul Hertz Award, which Asome of these initiatives might be supported in the future. recognizes contributions in radionu- In 2015 we published a book, The Highlights Lectures clide therapy. The inaugural recipient 1981–2009, with summaries of the highlight presentations by was Steven M. Larson, MD, from Henry N. Wagner, Jr., MD, at SNM Annual Meetings during Memorial Sloan–Kettering Cancer this period. It is a fascinating look through almost 30 years of Center (MSKCC; New York, NY). history in our field as seen by one of our most beloved pioneers. At a special symposium in conjunc- This volume is available through the SNMMI bookstore at tion with this award, Wolfgang http://www.snmmi.org/Store/Bestsellers.aspx?metadataid584. A. Weber, MD, also from MSKCC, Two significant anniversaries were celebrated in 2016. introduced the awardee. Dr. Larson Frederic Fahey, DSc The first was the 40th anniversary of the first human imaging and Richard P. Baum, MD, with 18F-FDG. Joanna Fowler, PhD, presented the Henry N. PhD, from the Zentralklinik Wagner, Jr., Lecture at the opening plenary session of the Bad Berka (Germany), pre- 2016 SNMMI Annual Meeting and wonderfully summarized sented lectures on thera- the activities leading up to this landmark event. She focused nostics. Barbara Hertz, on the groundbreaking work of Alfred P. Wolf, PhD, at the Dr. Hertz’s daughter, Brookhaven National Laboratory (Upton, NY), and the lab’s attended the symposium. collaboration with the group under David E. Kuhl, MD, at the The SNMMI Development University of Pennsylvania (Philadelphia). As a participant in Department, led by Larry the events, Dr. Fowler provided an exciting and insightful Dilworth and Teresa Ellmer, overview of the extraordinary logistics and coordination re- worked with Ms. Hertz on quired in 1976 to prepare the imaging agent in Brookhaven an exhibit honoring her fa- and deliver it to Penn for first-in-human imaging. ther as part of the SNMMI The year 2016 also marked the 75th anniversary of the first development booth at the radioiodine treatment at Massachusetts General Hospital Annual Meeting. This 20- (Boston, MA) by Saul Hertz, MD. In 1938, the John and panel exhibit included let- This volume, released at the Mary R. Markle Foundation of New York (NY) had provided ters exchanged between SNMMI 2016 Annual Meeting, funding for the cyclotron that supplied radioiodine for the 1941 Dr. Hertz and Karl Compton, contains the annual highlights treatment. SNMMI contacted the Markle Foundation, which PhD, president of the lectures delivered by Henry N. Wagner, Jr., MD, from 1981 graciously provided funds to help support the anniversary Massachusetts Institute of to 2009. celebration of the first radioiodine treatment. The History Technology at the time; Session at the Annual Meeting (our 7th in the series) focused pages from Dr. Hertz’s lab notebook documenting his first on the history of radionuclide therapy. Rodney J. Hicks, patients; and testimonies from grateful radioiodine therapy MBBS, MD, from the Peter MacCallum Cancer Centre recipients. (Melbourne, Australia), gave an informative and entertaining The Wall of Remembrance, which was introduced a presentation on medical uses of radium, from early use of few years ago to commemorate notable members who 226Ra to the more recent development of 223Ra-dichloride have passed away in the past 5 years, was displayed and (Xofigo) for treatment of bone metastases in prostate cancer. very well received at the SNMMI 2016 Annual Meeting. Frederick D. Grant, MD, from Boston Children’s Hospital SNMMI has consulted over the past year with a (MA), discussed the events leadingtoDr.Hertz’swork. professional archivist on organization of the materials in Edward Silberstein, MD, of the University of Cincinnati Col- the current SNMMI historical archive and on development lege of Medicine (OH), courageously covered all other radio- of a plan for moving forward. The goal was to detail a clear nuclides used for therapy over the years. This fascinating strategy for the most efficient and effective approach to session was presented to a full room of receptive attendees. preserving these materials and making them available to a Working with the SNMMI Radiopharmaceutical Sciences Council and the newly formed Radionuclide Therapy Center (Continued on page 20N) Newsline 19N SNMMI LEADERSHIP UPDATE FDA Approval of Imaging Agents: An Exciting Investment NEWSLINE in Nuclear Medicine Sally W. Schwarz, MS, RPh, BCNP, SNMMI President ith the recent U.S. Food and Drug Administration reader training for both Axumin (FDA) approval of 2 new PET diagnostic drugs, and NETSPOT that is available for WAxumin (fluciclovine 18F injection), for detecting free online. biochemical recurrence of prostate cancer, and NETSPOT As this issue of the magazine (68Ga-dotatate injection), for localization of somatostatin goes to print, we are awaiting word receptor–positive neuroendocrine tumors (NETs) in adult and on FDA approval of Lutathera pediatric patients, the field of nuclear medicine and molecular (177Lu-dotatate), which was granted imaging is beginning the new year on a high note. priority review in June last year, The approval of these PET diagnostic drugs is especially with a decision set for December good news for patients. In addition to providing improved 28, 2016. Lutathera is a new pep- imaging, NETSPOT delivers a lower radiation dose than the tide-receptor radionuclide therapy Sally W. Schwarz, SPECT alternative for NET imaging, which makes it more (PRRT) that targets neuroendocrine MS, RPh, BCNP convenient. The SPECT study can require up to 72 hours, carcinoid tumors with radiolabeled somatostatin analogue whereas NETSPOT provides results within 2 hours. Axumin peptides. Lutathera would work in tandem with NET- offers the availability of an 18F-labeled PET diagnostic for SPOT—first diagnosis of the target cancer tissue using NET- prostate cancer recurrence that can be produced offsite and SPOT, then delivery of the PRRT to cancer cells identified by distributed to a larger number of hospitals than the currently NETSPOT. Such companion diagnostics are truly the future approved 11C diagnostic. In addition, local Centers for Medi- of personalized medicine! care & Medicaid Services reimbursement for both Axumin Once Lutathera is approved, the Therapy Center of and NETSPOT followed their FDA approval, so patients can Excellence will conduct outreach to referring physicians immediately benefit from use of these PET drugs. and has already planned an educational session for the 2017 I am pleased to report that SNMMI’s Clinical Trials SNMMI Annual Meeting in Denver, CO. Network (CTN) was instrumental in the approval process The effectiveness of these new imaging agents and their for both Axumin and NETSPOT—helping with some of the success in gaining FDA approval and reimbursement hold key components of the Axumin trial (e.g., providing reader promise for further investment in nuclear medicine and training) and facilitating a shortened regulatory review for molecular imaging. In turn, more physicians and scientists NETSPOT. will be encouraged to pursue a molecular imaging career SNMMI’s Nuclear Medicine Clinical Trial Group, LLC, path. The future is, indeed, bright for our field! assists sponsors with effectively incorporating molecu- I wish everyone a happy, productive new year and look lar imaging agents in multicenter trials through a vari- forward to working with you to expand the frontiers of mole- ety of proven CTN-developed tools. It has developed cular imaging and provide ever more effective health care. (Continued from page 19N) wider audience of interested scholars and researchers. It is support needed to move into the next phase of our archive clear that this effort will require a long-term investment of plan as well as for long-term storage and management of time and dollars. As a result, SNMMI, in collaboration with these materials. The Heritage Campaign will be launched in the Education and Research Foundation for Nuclear Medicine early 2017, and SNMMI members will be kept informed of and Molecular Imaging, is developing a Heritage Fundraising opportunities to participate. Campaign for both the short and long terms. The expectation Please visit our website at www.snmmi.org/history, and do is for the Heritage Campaign to raise funds from individuals, not hesitate to contact me ([email protected]) with any corporate partners, and foundations that will provide the questions or comments. 20N THE JOURNAL OF NUCLEAR MEDICINE • Vol. 58 • No. 1 • January 2017.
Load more

Recommended publications
  • HISTORY Nuclear Medicine Begins with a Boa Constrictor
    HISTORY Nuclear Medicine Begins with a Boa Constrictor Marshal! Brucer J Nucl Med 19: 581-598, 1978 In the beginning, a boa constrictor defecated in and then analyzed the insoluble precipitate. Just as London and the subsequent development of nuclear he suspected, it was almost pure (90.16%) uric medicine was inevitable. It took a little time, but the acid. As a thorough scientist he also determined the 139-yr chain of cause and effect that followed was "proportional number" of 37.5 for urea. ("Propor­ inexorable (7). tional" or "equivalent" weight was the current termi­ One June week in 1815 an exotic animal exhibi­ nology for what we now call "atomic weight.") This tion was held on the Strand in London. A young 37.5 would be used by Friedrich Woehler in his "animal chemist" named William Prout (we would famous 1828 paper on the synthesis of urea. Thus now call him a clinical pathologist) attended this Prout, already the father of clinical pathology, be­ scientific event of the year. While he was viewing a came the grandfather of organic chemistry. boa constrictor recently captured in South America, [Prout was also the first man to use iodine (2 yr the animal defecated and Prout was amazed by what after its discovery in 1814) in the treatment of thy­ he saw. The physiological incident was common­ roid goiter. He considered his greatest success the place, but he was the only person alive who could discovery of muriatic acid, inorganic HC1, in human recognize the material. Just a year earlier he had gastric juice.
    [Show full text]
  • Radioiodine Therapy in Differentiated Thyroid Cancer – a Matter of Controversy – PRO Radioiodine
    Journal of Nuclear Medicine, published on May 10, 2018 as doi:10.2967/jnumed.117.191338 Radioiodine therapy in differentiated thyroid cancer – a matter of controversy – PRO Radioiodine Matthias Schmidt, Rainer Görges, Alexander Drzezga, Markus Dietlein Address for correspondence: Prof. Dr. Matthias Schmidt Department of Nuclear Medicine, University Hospital of Cologne Kerpener Str. 62, D – 50937 Koeln (Cologne), Germany P.: +492214785024, F.: +492214786777, E-Mail:<[email protected]> Abstract: Radioiodine therapy is a matter of controversy as different opinions exist towards its use in patients with differentiated thyroid carcinoma. The following article sheds light on different opinions and explains why the authors advocate the use of radioiodine therapy not only in high- risk patients. In comparison to other malignancies differentiated thyroid carcinoma has a different tumor biology due to its usually slow growth pattern. Radioiodine therapy was first used about 75 years ago and provided cure at a time when prospective randomized controlled trials were to be developed. Large patient cohorts and usually at least a decade of clinical follow-up are needed to demonstrate a benefit of radioiodine therapy. Thus, many factors define an individual treatment decision, especially in low risk patients including tumor stage, extent of surgery, tumor biology, clinical and imaging data, life expectancy and patients preferences. Learning Objectives: The reader should (1) know that radioiodine therapy was first introduced about 75 years ago; (2) describe special features of thyroid carcinoma tumor biology in comparison to other malignancies; (3) be able to explain which retrospective studies are needed to favorably value the clinical usefulness of radioiodine therapy; (4) find arguments for and against the use of radioiodine in different tumor stages.
    [Show full text]
  • Discoverers of Thyroid Landmarks
    Clark T. Sawin, MD July, 2002 Discoverers of Thyroid Landmarks Jean-François Coindet Caleb H. Parry Robert J. Graves Adolphe Chatin William W. Gull George R. Murray Edward C. Kendall David Marine Charles R. Harington Saul Hertz Edwin B. Astwood Jean-François Coindet (1774-1834) and the Treatment of Goiter with Iodine Jean-François Coindet was the first to realize that iodine could be a successful treatment for goiter. Iodine had just been discovered a few years before the publication in 1820 of his lecture that startled his Genevan colleagues. For some centuries, seaweed and burnt sea-sponge had been well-used folk medicines to treat goiter. Coindet suspected that, because of the way that iodine had been discovered as a residue of extracted seaweed, iodine itself might be the active ingredient in burnt sponge that affected goiter. He tried it and it worked. Coindet was a native Genevan who went to Edinburgh, then a mecca for medical training, for his MD and returned to Geneva in 1799 to begin his medical practice. He was quite successful and even at one point represented Geneva in the Swiss confederation. Goiter was particularly well-known in many areas of Switzerland although the cause was obscure. When Coindet thought that iodine might be good for goiter, he had a sample of sea sponge tested just to be sure it contained iodine: it did. So he abandoned the use of natural products and used iodine directly. His paper was picked up all around Europe, including an English translation in a London medical journal, and the treatment was tried equally widely.
    [Show full text]
  • We Commemorate Today the 80Th Anniversary of the First Therapeutic Use of Radioactive Sodium Iodide (I-130) Given to a Young Woman with Graves’ Disease by Dr
    We commemorate today the 80th Anniversary of the first therapeutic use of radioactive sodium iodide (I-130) given to a young woman with Graves’ Disease by Dr. Saul Hertz in 1941. The title banner is a clip from the table made by the legendary physician who conceived the idea, studied iodine kinetics on the animal model, and finally took it to the clinic by literally running a vial with radioactive iodine (RAI) from the cyclotron facility at the Massachusetts Institute of Technology (MIT) to the Thyroid Unit at the Massachusetts General Hospital (MGH) where he was the Clinical Director. The first patient, a young woman suffering from Graves’ disease, was waiting for him to bring the novel radioactive medicine for her experimental treatment! This remarkable story would not have happened if not for a eureka moment that occurred on November 11th, 1936 when Dr. Hertz sat listening to a lecture at MIT on how elements can be made radioactive. He was taking a break from clinical work and the animal research on thyroid iodine metabolism that required tedious measurements of tiny amounts of stable iodine. Understandably, he could hardly wait till the end of the lecture to ask the burning question – can iodine be made radioactive? But the answer was not immediately available and the lector, Professor Compton, wrote back to Dr. Hertz on December 15th, 1936 that while radioactive iodine is not well defined yet, it can be done! But as it turns out, to get enough of it for animal experiments and possibly therapeutic trials, it would require a cyclotron! A novelty at the time, the only one available in the U.S.A.
    [Show full text]
  • January Is Thyroid Month
    JANUARY 2016 THE LEADING MAGAZINE FOR ENDOCRINOLOGISTS JANUARY IS THYROID MONTH: IsIBitiSki Biotin Skewing Your Y Patient’s Test Results? YouYou may be treating them for somethingsome they don’t even have TheT Colorful Saga of Radioiodine Therapy HowHow a legendary thyroid treatment evolved from one man’s simple question Is Thyroid Cancer Screening Going to the Dogs? These pups have a remarkably high success rate in detecting cancer MMENTORINGENTORING IINN TTHEHE LLABAB Cultivating a new generation of researchers 22016016 LLAUREATEAUREATE AAWARDWARD WWINNERSINNERS Meet the new class of endocrinology pioneers Proud to be one of the nation’s largest comprehensive endocrinology programs. We’re one of the largest multidisciplinary programs to offer comprehensive evaluation and management of pediatric obesity. With cutting-edge research and a clinical and academic affiliation with UT Southwestern Medical Center, our diabetes program is one of the largest in the nation and was the first to receive the Disease Specific Care Certification for Diabetes by The Joint Commission. Home to the only transgender pediatric program in the southwestern United States, our endocrinology team is making major strides in health care. Visit childrens.com/excellence to learn more. IN THIS ISSUE JANUARY 2016 FEATURE 26 | Clash of the Titans: THE SAGA OF RADIOIODINE THERAPY The history of treating the thyroid with radioiodine is fraught with battles in labs, universities, prestigious medical journals, and even World War II. BY DEREK BAGLEY COVER STORY FEATURE PRACTICE RESOURCES 12 | Beware 17 | 2016 Laureate 34 | Who Let of Biotin Award Winners the Dogs Out? More patients are taking the dietary For more than 70 years, the Endocrine Thyroid cancer-sniffi ng dogs have a supplement biotin, which could be Society has recognized the achievements of remarkable success rate.
    [Show full text]
  • Radioiodine Therapy for Differentiated Thyroid Cancer Royal Marsden
    The ideal targeted therapy - Radioiodine and the thyroid V Ralph McCready Royal Sussex County Hospital Brighton UK Institute of Cancer Research Sutton Surrey The ideal targeted therapy - Radioiodine and the thyroid History of radioiodine Benign thyroid disease Malignant thyroid disease Suggestions for research Radioactive iodine First human use was 75 years ago • 1936 Hertz wondered if I -131 could be made • 1937 He made studies on rabbits with I -128 and found that hyperplastic glands increased absorption • 1938 Iodine-131 (131I), was discovered by Glenn Seaborg and John Livingood at the University of California, Berkeley • 1941 January 1st, Saul Hertz administered cyclotron produced a I-130 - I-131 mixture as the first therapeutic dose to a human patient with Graves’ Dr Saul Hertz disease at Massachusetts General Hospital. • 1946 May published a series of 29 patients with radioactive Iodine in the study of thyroid physiology Hertz S, Roberts A, Salter WT. Radioactive iodine as an indicator in Hertz S, Roberts A 1946 Radioactive iodine in the study of thyroid thyroid physiology, IV: the metabolism of iodine in Graves’ disease. physiology. VII The use of radioactive iodine therapy in Journal of Clinical Investigation 1942;21:25-29. hyperthyroidism. JAMA 131:81–86 75th I 131 Anniversary – Barcelona EANM 2016 Barbara Hertz Daughter Saul Hertz The I-131 story starts with the discovery of Iodine-127 in 1811 Bernard Courtois in 1811. while routinely processing the ash from seaweed to recover sodium and potassium compounds, he released a curious violet vapour that condensed into attractive iodine crystals. Dr Romsai Suwanik, Siriaj Hospital Bangkok Wanted to overcome iodine deficiency in Thai people Showed villagers how to make clay pots using flip charts Studies on Iodine Nutrition in Thailand RICHARD H.
    [Show full text]
  • The Blood Picture in Exophthalmic Goitre and Its Changes Resulting from Iodine and Operation. a Study by Means of the Supravital Technique
    THE BLOOD PICTURE IN EXOPHTHALMIC GOITRE AND ITS CHANGES RESULTING FROM IODINE AND OPERATION. A STUDY BY MEANS OF THE SUPRAVITAL TECHNIQUE Saul Hertz, J. Lerman J Clin Invest. 1932;11(6):1179-1196. https://doi.org/10.1172/JCI100471. Research Article Find the latest version: https://jci.me/100471/pdf THE BLOOD PICTURE IN EXOPHTHALMIC GOITRE AND ITS CHANGES RESULTING FROM IODINE AND OPERATION. A STUDY BY MEANS OF THE SUPRAVITAL TECHNIQUE By SAUL HERTZ 1 AND J. LERMAN (From the Thyroid Clinic and Metabolism Laboratory of the Massachusetts General Hospital Boston) (Received for publication April 29, 1932) The purpose of this report is to record a series of cases of exophthalmic goitre studied intensively by the supravital technique of blood examina- tion. This method was chosen as being particularly suited to the problem since it affords a clear differentiation of the large lymphocyte, monocyte and transitional polymorphonuclear cells, a distinction which is not always possible in the ordinary type of fixed smear. HISTORICAL While Ciuffini (1) described relative lymphocytosis in exophthalmic goitre in 1904, this aspect of the disease did not attract universal attention until the publications of L. Caro (2) (3). In the year 1907 the latter author described a case of fatal exophthalmic goitre with such atypical findings in the blood that he thought he was dealing with an associated pseudoleukemia. Later (1908) he collected a series of cases showing similar blood pictures. Caro was further- more able to produce the changes in the blood of normal individuals by the oral administration of thyroid gland. He showed that patients with non-toxic varieties of goitre did not have any alteration in their blood picture.
    [Show full text]
  • Headline the DISCOVERY of Technetium-‐99M and Iodine-‐131. Authors
    Headline THE DISCOVERY of technetium-99m and iodine-131. Authors Sergio Modoni (1) Nicoletta Urban (2) Luigi Mansi (3) (1) Nuclear Medicine, Oncological Referral Center of Basilicata, Rionero in Vulture (PZ) (2) Division of Nuclear Medicine, European Institute of Oncology, Milan. (3) Chair of Nuclear Medicine, Faculty of Medicine and Surgery, 2nd University of Naples. For correspondence: Sergio Modoni Unit of Nuclear Medicine Oncological Referral Center of Basilicata Prov.le Road 8 85028 Rionero in Vulture (PZ) tel.: 0972 726340 Mobile. 333 2822062 e mail: [email protected] Introduction Technetium-99m (99m Tc) and iodine-131 (131 I) are the everyday tools of Nuclear Physician. The discovery of these radioisotopes, as well as constitute a crucial step in the history of radiation in medicine, it also intersects with crucial events of the last century, with the most important discoveries in the field of physics of radiation, which is no stranger to the Italian genius, and events that have improved and sometimes shocked, but determined the history of humanity. Some premises of physics In the light of the knowledge acquired, we now know that the nucleus of an atom there are Z protons and N neutrons and Z that identifies the atomic number and the mass number A is given by the sum of N + Z, ie the number of protons and neutrons present in the nucleus of that element. Therefore, a nuclide of an element is identified by the values of A and Z and its symbol is: Nuclides with the same atomic number (Z) and different mass number (A) are called isotopes: Until 1919, the only known nuclear phenomena were those related to natural radioactivity produced by the last 12 elements of the periodic system, with Z from 81 to 92.
    [Show full text]
  • Dr. Saul Hertz Discovers the Medical Uses of Radioiodine (RAI) ISSN 2573-7724 Barbara Hertz* 6 Buckthorne Lane Greenwich, CT 06830, USA
    Open Access Journal of Radiology and Oncology Historical Vignette Dr. Saul Hertz Discovers the Medical Uses of Radioiodine (RAI) ISSN 2573-7724 Barbara Hertz* 6 Buckthorne Lane Greenwich, CT 06830, USA Primary sources document Dr. Saul Hertz (1905 - 1950) as conceiving and developing *Address for Correspondence: Barbara Hertz, M.ED. 6 Buckthorne Lane Greenwich, CT 06830, radioiodine (RAI) as a diagnostic tool and as a therapy for thyroid diseases. Dr. USA, Tel: 203-661-0777; Email: [email protected] Hertz was the irst and foremost person to develop the experimental data on RAI and Submitted: 09 August 2018 apply it to the clinical setting. Approved: 12 September 2018 Published: 13 September 2018 Saul Hertz was born on April 20,1905 to Jewish parents who had immigrated to Copyright: © 2018 Hertz B. This is an open Cleveland, Ohio. He received his A.B. from the University of Michigan in 1925 with Phi access article distributed under the Creative Beta Kappa honors. After graduating from Harvard Medical School in 1929, at a time of Commons Attribution License, which permits quotas for outsiders, he fulilled his internship and residency at Cleveland’s Mt. Sinai unrestricted use, distribution, and reproduction in any medium, provided the original work is Hospital. properly cited. In 1931, he came back to Boston to join the newly formed Thyroid Unit at The Massachusetts General Hospital serving as the Chief from 1931 - 1943. On November 12, 1936 Dr. Karl Compton, president of the Massachusetts Institute of Technology, spoke at a luncheon lecture at Harvard Medical School. His topic was What Physics can do for Biology and Medicine.
    [Show full text]
  • Legacy of Dr. Saul Hertz Focus of Special Exhibit NOV Daylight Savings 2 Time Ends
    NOVEMBER 2014 @ theBradbury Special News & Events Save the Date! Legacy of Dr. Saul Hertz Focus of Special Exhibit NOV Daylight Savings 2 Time Ends NOV Scientists in the Spotlight 8 11:00 AM TO 1:00 PM Chat with scientists about supernovae or aquatic biology. All ages welcome. NOV Veterans Day 11 Thank you to our nation’s heroes. NOV Exhibit Opening 18 Saul Hertz, MD: A Pioneer in the Use of Radioactive Isotopes NOV Science On Tap Bradbury Science Museum Director, Linda Deck, and Exhibit 20 5:30 PM to 7:00 PM Designer, Omar Juveland, begin unpacking a special exhibit @ Manhattan Project on loan from Barbara Hertz, daughter of medical pioneer, 1789 Central Avenue Dr. Saul Hertz. This exhibit will open at the museum Los Alamos, NM beginning Tuesday, November 18 and remain on display NOV Thanksgiving Holiday through Saturday, January 31. To learn more about what 27 Museum will be CLOSED makes this exhibit so fascinating, continue to page 3. 1350 Central Avenue (505) 667-4444 Los Alamos, NM 87544 www.lanl.gov/museum @ THE BRADBURY NOVEMBER 2014 Monthly, Every Second Saturday Beginning November 8, 2014 Starting in November, the museum is introducing a new monthly program called Scientist in the Spotlight featuring Scientist Ambassadors that have recently been certified through the museum’s Scientist Ambassador Academy program. In this activity, scientists will be on the museum floor for a few hours having casual conversations with patrons about their favorite Science, Technology, Engineering, or Math (STEM) subject. Scientist in the Spotlight will happen every second Saturday of the month beginning Saturday, November 8 when Nicole Lloyd-Ronning will talk about supernovae and Jane Clements will discuss aquatic biology.
    [Show full text]
  • Isotopes of Iodine 1 Isotopes of Iodine
    Isotopes of iodine 1 Isotopes of iodine There are 37 known isotopes of iodine (I) from 108I to 144I, but only one, 127I, is stable. Iodine is thus a monoisotopic element. Its longest-lived radioactive isotope, 129I, has a half-life of 15.7 million years, which is far too short for it to exist as a primordial nuclide. Cosmogenic sources of 129I produce very tiny quantities of it that are too small to affect atomic weight measurements; iodine is thus also a mononuclidic element—one that is found in nature essentially as a single nuclide. Most 129I derived radioactivity on Earth is man-made: an unwanted long-lived byproduct of early nuclear tests and nuclear fission accidents. All other iodine radioisotopes have half-lives less than 60 days, and four of these are used as tracers and therapeutic agents in medicine. These are 123I, 124I, 125I, and 131I. Essentially all industrial production of radioactive iodine isotopes A Pheochromocytoma is seen as a involves these four useful radionuclides. dark sphere in the center of the body The isotope 135I has a half-life less than seven hours, which is too short to be (it is in the left adrenal gland). Image is by MIBG scintigraphy, with used in biology. Unavoidable in situ production of this isotope is important in radiation from radioiodine in the 135 nuclear reactor control, as it decays to Xe, the most powerful known neutron MIBG. Two images are seen of the absorber, and the nuclide responsible for the so-called iodine pit phenomenon. same patient from front and back.
    [Show full text]
  • Isolation Period of 131I Administered Patients at Nimra Jamshoro Pakistan
    International Journal of Radiology & Radiation Therapy Research Article Open Access Isolation period of 131i administered patients at nimra jamshoro Pakistan Abstract Volume 2 Issue 1 - 2017 Objectives: Since 1940s, the clinical use of unsealed radioisotopes has been in practice and after that the radioiodine’s oral administration became a gold standard Sajjad Ahmed Memon, Naeem Ahmed for treating thyroid cancers. To protect the patients’ family members/caregivers and Laghari, Fayaz Hussain Mangi, Muhammad general public from unacceptably high radiation exposures, the therapeutic dosage of Mubashar Hussain, Sadiq Hussain Nohario 131I administered patients are mandatory hospitalized in special isolation room until the Nuclear Institute of Medicine and Radiotherapy (NIMRA), exposure rate at one meter meets international and national limits. The current study Pakistan was focused to measure the isolation duration of inpatients treated with radioiodine. Correspondence: Sajjad Ahmed Memon, Nuclear Institute of Material and methods: The current study presents the duration of hospitalization Medicine and Radiotherapy (NIMRA), Jamshoro, Pakistan, Tel of patients treated with 131I therapeutic dosages at Nuclear Institute of Medicine & 923003055291, Email [email protected] Radiotherapy (NIMRA) Jamshoro, Pakistan from 2011 to 2013. Thirty Five patients (age range from 18 to 70years) with cancer of thyroid administered with different Received: October 02, 2016 | Published: January 03, 2017 activities (50 to 200mCi (milliCurie)) of 131I admitted in special isolated room at different times were included in this study. Results: The results indicated that only one (2.86%) of total patients discharged from hospital within first 24hours of 131I administration whereas 17(48.57%), 11(31.43%) and 3(8.57%) patients were hospitalized in isolation room for 48, 72 and 96hours after the administration of activity.
    [Show full text]